Research ethics in the post-genomic era

Environmental and Molecular Mutagenesis

Volumn 54, Issue 7, 2013, Pages 599-610

  Vähäkangas, Kirsi ^a  

^a UNIVERSITY OF EASTERN FINLAND   (Finland)

Author keywords

Autonomy; Genomic studies; Privacy; Research integrity; Validation

Indexed keywords

BIOBANK; BIOINFORMATICS; BREAST CANCER; CANCER PROGNOSIS; CONFIDENTIALITY; DISEASE PREDISPOSITION; GENE EXPRESSION; GENETIC ASSOCIATION; GENETIC DISORDER; GENETIC TRAIT; GENOMICS; HEALTH CARE FACILITY; HIGH THROUGHPUT SEQUENCING; INFORMATION TECHNOLOGY; INFORMED CONSENT; LAW; PERSONALIZED MEDICINE; PRACTICE GUIDELINE; PRIVACY; PROFESSIONAL STANDARD; QUALITY CONTROL; RESEARCH ETHICS; REVIEW; TRANSLATIONAL RESEARCH;

AUTONOMY; GENOMIC STUDIES; PRIVACY; RESEARCH INTEGRITY; VALIDATION;

ETHICS, RESEARCH; GENOMICS; HUMANS; TISSUE BANKS;

EID: 84882256193     PISSN: 08936692     EISSN: 10982280     Source Type: Journal    
DOI: 10.1002/em.21804     Document Type: Review

References (95)

1. Baggerly KA, Coombes KR. 2011. What information should be required to support clinical "Omics" publications? Clin Chem 57:688-690.
2. Baggerly KA, Coombes KR, Neeley ES. 2008. Run batch effects potentially compromise the usefulness of genomic signatures for ovarian cancer. J Clin Oncol 26:1186-1187.
3. Barlow-Stewart K, Taylor SD, Treloar SA, Stranger M, Otlowski M. 2009. Verification of consumers' experiences and perceptions of genetic discrimination and its impact on utilization of genetic testing. Genet Med 11:193-201.
4. Bauer EA, Cohen DE. 2012. The changing roles of industry and academia. J Investigat Dermatol 132:1033-1036.
5. Beaudet AL. 2010. Which way for genetic-test regulation? Leave test interpretation to specialists. Nature 466:816-817.
6. Bellazzi R, Masseroli M, Murphy S, Shabo A, Romano P. 2012. Clinical bioinformatics: Challenges and opportunities. BMC Bioinform 13 (Suppl 14):S1.
7. Beskow LM, Friedman JY, Hardy NC, Lin L, Weinfurt KP. 2010. Developing a simplified consent form for biobanking. PLoS One 5:e13302.
8. Biau DJ, Jolles BM, Porcher R. 2010. P value and the theory of hypothesis testing: An explanation for new researchers. Clin Orthop Relat Res 468:885-892.
9. Brisson AR, Matsui D, Rieder MJ, Fraser DD. 2012. Translational research in pediatrics: Tissue sampling and biobanking. Pediatrics 129:153-162.
10. Budimir D, Polasek O, Marusić A, Kolcić I, Zemunik T, Boraska V, Jeroncić A, Boban M, Campbell H, Rudan I. 2011. Ethical aspects of human biobanks: A systematic review. Croat Med J 52:262-279.
11. Callaway E. 2011a. Aboriginal genome analysis comes to grips with ethics. Nature 477:522-523.
12. Callaway E. 2011b. Report finds massive fraud at Dutch universities. Nature 479:15.
13. Cambon-Thomsen A. 2004. The social and ethical issues of post-genomic human biobanks. Nat Rev Genet 5:866-873.
14. Coombes KR, Wang J, Baggerly KA. 2007. Microarrays: Retracing steps. Nat Med 13:1276-1277.
15. Crocker J. 2011. The road to fraud starts with a single step. Nature 479:151.
16. Currie RA. 2012. Toxicogenomics: The challenges and opportunities to identify biomarkers, signatures and thresholds to support mode-of-action. Mutat Res 746:97-103.
17. de Vries J, Pepper M. 2012. Genomic sovereignty and the African promise: Mining the African genome for the benefit of Africa. J Med Ethics 38:474-478.
18. de Vries J, Slabbert M, Pepper MS. 2012. Ethical, legal and social issues in the context of the planning stages of the Southern African Human Genome Programme. Med Law 31:119-152.
19. Durieux V, Gevenois PA. 2010. Bibliometric indicators: Quality measurements of scientific publication. Radiology 255:342-351.
20. Eijssen LM, Jaillard M, Adriaens ME, Gaj S, de Groot PJ, Müller M, Evelo CT. 2013. User-friendly solutions for microarray quality control and pre-processing on ArrayAnalysis.org. Nucleic Acids Res 41:W71-W76.
21. Fanelli D. 2010. Do pressures to publish increase scientists' bias? An empirical support from US states data. PLoS One 5:e10271.
22. Fang FC, Steen RG, Casadevall A. 2012. Misconduct accounts for the majority of retracted scientific publications. Proc Natl Acad Sci USA109:17028-17033.
23. Feldman MD, Huang L, Guglielmo BJ, Jordan R, Kahn J, Creasman JM, Wiener-Kronish JP, Lee KA, Tehrani A, Yaffe K, Brown JS. 2009. Training the next generation of research mentors: The University of California, San Francisco, Clinical and Translational Science Institute Mentor Development Program. Clin Transl Sci 2:216-221.
24. Fullerton SM, Lee SS. 2011. Secondary uses and the governance of de-identified data: Lessons from the human genome diversity panel. BMC Med Ethics 12:16.
25. Gerber P. 2006. What can we learn from the Hwang and Sudbø affairs? Med J Aust 184:632-635.
26. Glatt SJ, Stone WS, Nossova N, Liew CC, Seidman LJ, Tsuang MT. 2011. Similarities and differences in peripheral blood gene-expression signatures of individuals with schizophrenia and their first-degree biological relatives. Am J Med Genet B Neuropsychiatr Genet 156B:869-887.
27. Godlee F. 2011. Institutional research misconduct. Failings over the MMR scare may need parliamentary inquiry. Br Med J 343:d7284.
28. Godlee F, Wager E. 2012. Research misconduct in the UK. Time to act. Br Med J 344:d8357.
29. Gottweis H, Chen H, Starkbaum J. 2011. Biobanks and the phantom public. Hum Genet. 130:433-440.
30. Groisman IJ, Mathieu G, Godard B. 2012. Use of next generation sequencing technologies in research and beyond: Are participants with mental health disorders fully protected? BMC Med Ethics 13:36.
31. Helgesson G, Dillner J, Carlson J, Bartram CR, Hansson MG. 2007. Ethical framework for previously collected biobank samples. Nat Biotechnol 25:973-976.
32. Hewitt R, Hainaut P. 2011. Biobanking in a fast moving world: An international perspective. J Natl Cancer Inst Monogr 42:50-51.
33. Hofmann BM. 2008. Bypassing consent for research on biological material. Nat Biotechnol 26:979-980.
34. Hofmann B, Myhr AI, Holm S. 2013. Scientific dishonesty-A nationwide survey of doctoral students in Norway. BMC Med Ethics 14:3.
35. International Society for Biological and Environmental Repositories. 2012. Best practices for repositories. Collection, storage, retrieval and distribution of biological materials and research. Biopreserv Biobank 10:81-161.
36. Javitt G. 2010. Which way for genetic-test regulation? Assign regulation appropriate to the level of risk. Nature 466:817-818.
37. Joh EE. 2011. Ethics watch: DNA theft: your genetic information at risk. Nat Rev Genet 12:808.
38. Kaufman D, Geller G, LeRoy L, Murphy J, Scott J, Hudson K. 2008. Ethical implications of including children in a large biobank for genetic-epidemiologic research: A qualitative study of public opinion. Am J Med Genet Part C Semin Med Genet 148C:31-39.
39. Klemperer D. 2010. Drug research: Marketing before evidence, sales before safety. Dtsch Arztebl Int 107:277-278.
40. Kornfeld DS. 2012. Perspective: Research misconduct: The search for a remedy. Acad Med 87:877-882.
41. Kramer S, Soskolne CL, Mustapha BA, Al-Delaimy WK. 2012. Revised ethics guidelines for environmental epidemiologists. Env Health Perspect 120:A299-A301.
42. Kriegeskorte N. 2012. Open evaluation: A vision for entirely transparent post-publication peer review and rating for science. Front Comput Neurosci 6:79.
43. Kwon SM, Cho H, Choi JH, Jee BA, Jo Y, Woo HG. 2012. Perspectives of integrative cancer genomics in next generation sequencing era. Genomics Inform 10:69-73.
44. Lin Z, Owen AB, Altman RB. 2004. Genetics. Genomic research and human subject privacy. Science 305:183.
45. Lovén J, Orlando DA, Sigova AA, Lin CY, Rahl PB, Burge CB, Levens DL, Lee TI, Young RA. 2012. Revisiting global gene expression analysis. Cell 151:476-482.
46. Lowrance WW, Collins FS. 2007. Identifiability in genomic research. Science 317:600-602.
47. MacArthur D. 2012. Face up to false positives. Comment. Nature 487:427-428.
48. Manolio TA, Weis BK, Cowie CC, Hoover RN, Hudson K, Kramer BS, Berg C, Collins R, Ewart W, Gaziano JM, Hirschfeld S, Marcus PM, Masys D, McCarty CA, McLaughlin J, Patel AV, Peakman T, Pedersen NL, Schaefer C, Scott JA, Sprosen T, Walport M, Collins FS. 2012. New models for large prospective studies: Is there a better way? Am J Epidemiol 175:859-866.
49. Marguerat S, Bähler J. 2012. Coordinating genome expression with cell size. Trends Genet 28:560-565.
50. Melas PA, Sjöholm LK, Forsner T, Edhborg M, Juth N, Forsell Y, Lavebratt C. 2010. Examining the public refusal to consent to DNA biobanking: empirical data from a Swedish population-based study. J Med Ethics 36:93-98.
51. Melo DG, Squeiros J. 2012. The challenges of incorporating genetic testing in the unified health system in Brazil. Gen Testing Mol Biomarkers 16:651-655.
52. Merlo DF, Knudsen LE, Matusiewicz K, Niebrój L, Vähäkangas KH. 2007. Ethics in studies on children and environmental health. J Med Ethics 33:408-413.
53. Merlo DF, Vahakangas K, Knudsen LE. 2008. Scientific integrity: Critical issues in environmental health research. Environ Health 7 (Suppl 1):S9.
54. Neri M, Bonassi S, Knudsen LE, Sram RJ, Holland N, Ugolini D, Merlo DF. 2006. Children's exposure to environmental pollutants and biomarkers of genetic damage. I. Overview and critical issues. Mutat Res 612:1-13.
55. Ocaña A, Pandiella A. 2010. Personalized therapies in the cancer "omics" era. Mol Cancer 9:202.
56. O'Doherty KC, Hawkins AK, Burgess MM. 2012. Involving citizens in the ethics of biobank research: Informing institutional policy through structured public deliberation. Soc Sci Med 75:1604-1611.
57. Offit K. 2011. Personalized medicine: New genomics, old lessons. Hum Genet 130:3-14.
58. Patenaude AF. 2011. Commentary: Save the children: Direct-to-consumer testing of children is premature, even for research. J Pediatr Psychol 36:1122-1127.
59. Pearson H. 2003. It's a scoop! Nature 426:222-223.
60. Pelkonen O, Pasanen M, Lindon JC, Chan K, Zhao L, Deal G, Xu Q, Fan TP. 2012. Omics and its potential impact on R&D and regulation of complex herbal products. J Ethnopharmacol 140:587-593.
61. Pendlebury DA. 2009. The use and misuse of journal metrics and other citation indicators. Arch Immunol Ther Exp 57:1-11.
62. Percy AJ, Chambers AG, Smith DS, Borchers CH. 2013. Standardized protocols for quality control of MRM-based plasma proteomic workflows. J Proteome Res 12:222-233.
63. Petrini C. 2010. "Broad" consent, exceptions to consent and the question of using biological samples for research purposes different from the initial collection purpose. Soc Sci Med 70:217-220.
64. Porteri C, Togni E, Pasqualetti P. 2013. The policies of ethics committees in the management of biobanks used for research: An Italian survey. Eur J Hum Genet. May 22. doi: 10.1038/ejhg.2013.107. [Epub ahead of print].
65. Pullman D, Etchegary H, Gallagher K, Hodgkinson K, Keough M, Morgan D, Street C. 2012. Personal privacy, public benefits, and biobanks: A conjoint analysis of policy priorities and public perceptions. Genet Med 14:229-235.
66. Qiu J. 2010. Publish or perish in China. Nature 463:142-143.
67. Reymond MA, Steinert R, Escourrou J, Fourtanier G. 2002. Ethical, legal and economic issues raised by the use of human tissue in postgenomic research. Dig Dis 20:257-265.
68. Ries NM, LeGrandeur J, Caulfield T. 2010. Handling ethical, legal and social issues in birth cohort studies involving genetic research: Responses from studies in six countries. BMC Med Ethics 11:4.
69. Roig M. 2012. Avoiding unethical writing practices. Editorial. Food Chem Toxicol 50:3385-3387.
70. Rosner D, Markowitz G. 2012. With the best intentions. Lead research and the challenge to public health. Am J Public Health 102:e19-e33.
71. Salvaterra E, Giorda R, Bassi MT, Borgatti R, Knudsen LE, Martinuzzi A, Nobile M, Pozzoli U, Ramelli GP, Reni GL, Rivolta D, Stazi MA, Strazzer S, Thijs C, Toccaceli V, Trabacca A, Turconi AC, Zanini S, Zucca C, Bresolin N, Lenzi L. 2012. Pediatric biobanking: A pilot qualitative survey of practices, rules and researcher opinions in ten European countries. Biopreserv Biobank 10:29-36.
72. Sankar P, Cho MK, Mountain J. 2007. Race and ethnicity in genetic research. Am J Med Genet A 143A:961-970.
73. Secko DM, Preto N, Niemeyer S, Burgess MM. 2009. Informed consent in biobank research: A deliberative approach to the debate. Soc Sci Med 68:781-789.
74. Skloot R. 2011. The Immortal Life of Henrietta Lacks, 2nd ed. New York: Random House Inc.
75. Snell K, Starkbaum J, Lauß G, Vermeer A, Helén I. 2012. From protection of privacy to control of data streams: A focus group study on biobanks in the information society. Public Health Genom 15:293-302.
76. Spitz MR, Bondy ML.2010. The evolving discipline of molecular epidemiology of cancer. Carcinogenesis 31:127-134.
77. Steen RG. 2011. Retractions in the scientific literature: Is the incidence of research fraud increasing? J Med Ethics 37:249-253.
78. Su Z, Ning B, Fang H, Hong H, Perkins R, Tong W, Shi L. 2011. Next-generation sequencing and its applications in molecular diagnostics. Expert Rev Mol Diagn 11:333-343.
79. Tavani HT. 2004. Genomic research and datamining technology: Implications for personal privacy and informed consent. Ethics Inf Technol 6:15-28.
80. Ugolini D, Neri M, Canessa PA, Casilli C, Catrambone G, Ivaldi GP, Lando C, Marroni P, Paganuzzi M, Parodi B, Visconti P, Puntoni R, Bonassi S. 2008. The CREST biorepository: A tool for molecular epidemiology and translational studies on malignant mesothelioma, lung cancer, and other respiratory tract diseases. Cancer Epidemiol Biomarkers Prev 17:3013-3019.
81. Vähäkangas K. 2001. Ethical implications of genetic analysis of individual susceptibility to diseases. Mutat Res 482:105-110.
82. Vähäkangas K. 2004. Ethical aspects of molecular epidemiology of cancer. Carcinogenesis 25:465-471.
83. Venet D, Dumont JE, Detours V. 2011. Most random gene expression signatures are significantly associated with breast cancer outcomes. PloS Comput BIol 7:e1002240.
84. Wang AT, Montori VM, Murad MH. 2010. Financial conflicts of interest in biomedical research: The need to improve the system. Drug News Perspect 23:607-612.
85. Watanabe M, Inoue Y, Chang C, Hong H, Kobayashi I, Suzuki S, Muto K. 2011. For what am I participating? The need for communication after receiving consent from biobanking project participants: Experience in Japan. J Hum Genet 56:358-363.
86. Watson RWG, Kay EW, Smith D. 2010. Integrating biobanks: Addressing the practical and ethical issues to deliver a valuable tool for cancer research. Nat Rev Cancer 10:646-651.
87. Wexler A. 1995. Mapping Fate: A Memoir of Family, Risk and Genetic Research. Times Books, Random House, New York.
88. Whitely WP, Rennie D, Hafner AW. 1994. The scientific community's response to evidence of fraudulent publication. The Robert Slutsky case. JAMA 272:170-173.
89. Whitley EA, Kanellopoulou N, Kaye J. 2012. Consent and research governance in biobanks: Evidence from focus groups with medical researchers. Public Health Genom 15:232-242.
90. Wilcken B. 2011. Ethical issues in genetics. J Paediatr Child Health 47:668-671.
91. Witten DM, Tibshirani R. 2013. Scientific research in the age of omics: The good, the bad, and the sloppy. J Am Med Inform Assoc 20:125-127.
92. Wolf SM, Crock BN, Van Ness B, Lawrenz F, Kahn JP, Beskow LM, Cho MK, Christman MF, Green RC, Hall R, Illes J, Keane M, Knoppers BM, Koenig BA, Kohane IS, LeRoy B, Maschke KJ, McGeveran W, Ossorio P, Parker LS, Petersen GM, Richardson HS, Scott JA, Terry SF, Wilfond BS, Wolf WA. 2012. Managing incidental findings and research results in genomic research involving biobanks and archived data sets. Genet Med 14:361-384.
93. Wonkam A, Kenfack MA, Muna WFT, Ouwe-Missi-Oukem-Boyer O. 2011. Ethics of human genetic studies in sub-Saharan Africa: The case of Cameroon through a bibliometric analysis. Dev World Bioeth 11:120-127.
94. Yang X, Liu D, Liu F, Wu J, Zou J, Xiao X, Zhao F, Zhu B. 2013. HTQC: A fast quality control toolkit for Illumina sequencing data. BMC Bioinform 14:33.
95. Yassin R, Lockhart N, González del Riego M, Pitt K, Thomas JW, Weiss L, Compton C. 2010. Custodianship as an ethical framework for biospecimen-based research. Cancer Epidemiol Biomarkers Prev 19:1012-1015.